Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2024, AbbVie (ABBV) reported revenue of $15.1 billion, up 5.6% over the same period last year. EPS came in at $2.16, compared to $2.79 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $14.87 billion, representing a surprise of +1.56%. The company delivered an EPS surprise of +1.41%, with the consensus EPS estimate being $2.13.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Oncology- Elahere- Total: $148 million versus $145.30 million estimated by six analysts on average. Net Revenue- Creon- US: $388 million versus the five-analyst average estimate of $347.75 million. The reported number represents a year-over-year change of +3.2%. Net Revenue- Immunology- Skyrizi- International: $466 million versus the five-analyst average estimate of $506.42 million. The reported number represents a year-over-year change of +61.3%. Net Revenue- Humira- US: $1.25 billion compared to the $1.53 billion average estimate based on five analysts. The reported number represents a change of -54.5% year over year. Net Revenue- Neuroscience- Total: $2.51 billion compared to the $2.47 billion average estimate based on six analysts. The reported number represents a change of +19.8% year over year. Net Revenue- Vraylar- Total: $924 million versus the six-analyst average estimate of $948.55 million. The reported number represents a year-over-year change of +17.1%. Net Revenue- Immunology- Total: $7.29 billion versus $7.25 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change. Net Revenue- Hematologic Oncology- Total: $1.69 billion compared to the $1.67 billion average estimate based on six analysts. The reported number represents a change of +12.1% year over year. Net Revenue- Rinvoq- Total: $1.83 billion versus $1.72 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +46.1% change. Net Revenue- Botox Therapeutic- Total: $873 million compared to the $880.31 million average estimate based on six analysts. The reported number represents a change of +12.5% year over year. Net Revenue- Botox Cosmetic- Total: $687 million versus the six-analyst average estimate of $756.46 million. The reported number represents a year-over-year change of -4.3%. Net Revenue- Venclexta: $655 million versus the six-analyst average estimate of $674.25 million. The reported number represents a year-over-year change of +11.2%. View all Key Company Metrics for AbbVie here>>>Shares of AbbVie have returned -2.1% over the past month versus the Zacks S&P 500 composite's +2.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks